OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

Annual Report & Accounts 2025 Staying well until a cure is found

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

CONTENTS

Message from our
Co-Founder & Chairman 1
Board of Trustees 2
Editorial Advisory Board 3-4
Our Purpose, Aims
& Activities 5-6
Awareness, Information
& Support 7-13
Research Advisory Board 14-15
Research 2025 16-21
Community Fundraising 22-27
Charitable Trusts 28
Giving in Memory 29
How to support us 30
Plans for 2026 & Beyond 31
Charity Information &
Governance 32-37
Trustees’ Responsibilities 38
Independent Auditor’s Report 39-41
Financial Statements 42-53

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

Message from our Co-Founder & Chairman

Dear Friends,

The year 2025 will be remembered as one of important achievements for the Diabetes Research & Wellness Foundation, and it gives me great pride to submit to you and all of our generous supporters, this Annual Report for 2025.

With your generous ongoing support we were able to:

  1. See the fruits of our years long funding efforts with the start of clinical human trials using the SpringPoint Project produced encapsulated pig pancreatic islet cells. As we have hoped for so many years, this novel cell therapy offers a new option for patients struggling with Type 1 diabetes.

  2. Continue our major support of the DRWF Islet Isolation Facility at the Churchill Hospital in Oxford, which is pivotal to delivering insulin producing cells for human transplant across the UK.

  3. We continued to award grants to early career researchers with a new Fellowship award.

Supporting early-career research fellowships and ‘pump-priming’ awards is vital because these funds give emerging scientists the chance to explore innovative ideas at the earliest stage. By backing promising talent and bold concepts before major grants are available, we spark the breakthroughs that can grow into tomorrow’s life-changing diabetes treatments.

As you read this 2025 Annual Report you will learn more about the research we are funding and about all of our other awareness and educational Wellness programmes. Like our Family Camp for families of children with type 1 diabetes and our United Through Diabetes programme which delivers accredited health and social care information to support people living with all types of diabetes. All of these activities are designed to provide the information and peer support necessary to tackle the daily challenges that life with diabetes presents. You should be proud of all this work, because without you, we could not have accomplished so much.

John Alahouzos Co-Founder & Chairman

I also want to thank and acknowledge our collaborative team of volunteers and staff led by DRWF’s Board of Trustees, our Research and Editorial Advisory Board members, and CEO Sarah Tutton and her dedicated staff.

Extending our proud record of achievements will be accomplished with your continued faith and support. With your help, DRWF will be well positioned to continue to carry out its mission to fund the research that will bring us THE CURE for diabetes, and until then, ensure that people with diabetes are staying well until a cure is found.

Sincerely,

John Alahouzos

Thank you again for your generosity.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 OUR BOARD OF TRUSTEES

Trustees

John Alahouzos

Co-Founder and Chairman of the Board

John Alahouzos is a marketing executive by profession and a volunteer fundraiser for the ‘Diabetes Cure’ by choice. For over 40 years he has worked to raise awareness and funds for the need to cure diabetes. John is chairman of DRWF UK and serves as a board member of DRWF Inc, as well as affiliates in France, Sweden, Finland and Norway.

Christian Gretschel

Non-profit fundraising professional

Chris has been a board member of the DRWF Inc. (US) since its inception in 1993 and joined the DRWF Board of Trustees in the UK in 2023. He was diagnosed with type 1 diabetes when he was two years old, and his eldest son, Jack, was diagnosed in 2023. Chris is passionate about helping the diabetes community stay healthy as we pursue our long-awaited cure.

Steve Jones

Business coach, public speaker, trainer and consultant Steve is an expert in creating ideas and strategies that build businesses, drive revenue and improve business position and performance. He has a passion for making companies and their products the best in their product category. Steve’s unique understanding of leadership and management, team building and motivation in business, coupled with his understanding, drive and enthusiasm, clearly set him aside as an expert.

Adrian Durelli

Seasoned healthcare executive and consultant

Adrian joined the DRWF board of Trustees in 2023. He is keenly interested in patient access and customer support, specialising in operations, sales & marketing strategy and leadership and has been a healthcare consultant to various health systems. Adrian’s dedicated interest in healthcare and expert knowledge in business development helps to drive DRWF’s purpose – to help those living with diabetes stay well until a cure is found.

2

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

EDITORIAL ADVISORY BOARD

Editorial Advisory Board

Healthcare Professionals

Dr Sarah Brewer GP Health Journalist and Specialist in Nutritional Medicine

Azmina Govindji, Registered Dietitian and TV Nutritionist

Andrea Cameron

Head of the School of Social and Health Sciences, Abertay University

Emma Howard Community Diabetes Lead Podiatrist, Oxford Health NHS Foundation Trust

Professor Edzard Ernst Professor in Complementary Medicine, Exeter

Dr Alison Kirk

Lecturer in Physical Activity for Health, University of Strathclyde, Glasgow

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

EDITORIAL ADVISORY BOARD

Bethany Kelly

Development Clinical Lead Diabetes Specialist Nurse, Wiltshire Health and Care

Dr Alastair Leckie

MBChB DRCOG MRCGP FFOM, Consultant in Occupational Medicine, OHSAS

Henrietta Mulnier

RGN MSc PhD RNT, Lead Diabetes Nurse, Royal Surrey County Hospital and Primary Care

Dr Mayank Patel Consultant Physician in Diabetes, University Hospital Southampton NHS Foundation Trust

Professor Philip Preshaw Specialist in Periodontics, Visiting Professor, Newcastle University

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

OUR PURPOSE, AIMS AND ACTIVITES

Our purpose, aims and activities

The objects of the charity are:

Since DRWF began in 1998, the number of people diagnosed with diabetes has more than doubled. Whilst there have been some incredible advances in treatment and technology in more recent times, which improve quality of life and reduce the risk of complications, the number of people living with diabetes continues to rise at an alarming rate.

In total there are more than 5 million people now living with diabetes in the UK with around 90% of this attributed to the rising tide of type 2 diabetes. The NHS has also identified as many as 6.3 million people at risk of developing type 2 diabetes based on blood sugar levels.

The UK has the 5th highest number of people living with type 1 diabetes, over 340,000 in 2024.

Early identification means that an earlier diagnosis can be made along with earlier support to prevent the condition progressing and reducing the associated risks of cardiovascular disease, kidney failure, lower limb amputation and sight loss.

Even so, over 27,000 people died due to diabetes related complications in 2024

Both type 1 and type 2 diabetes are progressive conditions meaning that people living with either condition are constantly navigating the health challenges that diabetes presents whilst the research we fund seeks a cure.

Our mission is to support people living with all types of diabetes by providing the ongoing information, education and peer support required to face the challenges of living with a long term, often complex, condition head on and lead the best quality of life possible.

Demonstrating public benefit

The trustees confirm that they have referred to the general guidance set out by Charity Commission on public benefit. The trustees are satisfied that the Charity’s activities meet the principles of public benefit, defined as providing an identifiable benefit/s to the public, or section of the public, and know of no detriment or harm that may be caused because of these activities, which are clearly set out throughout this report. We are committed to ensuring that the values of equality, diversity and inclusion are embedded respectfully into everything that we do. We endeavour to make the charity’s information, education and support services available to all.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 OUR PURPOSE, AIMS AND ACTIVITE2024 ACHIEVEMENTS: AWARENES S , INFORMATION & SUPPORT

Activities & Achievements in 2025

Amidst the financial difficulties facing all charities in the UK, DRWF are proud that we:

Measuring Impact

We use a mixed methods approach to monitor and evaluate our activities to ensure that they remain true to purpose and achieve desired outcomes. Stakeholders and beneficiaries are involved in these evaluation processes to ensure the continued relevance, quality, accessibility, and effectiveness of activities. We also undertake independent evaluation with specialist partners for specific projects where impartial opinion and/or additional expertise is required.

We keep people with diabetes at the heart of what we do. Beneficiaries and supporters are involved in numerous ways to ensure that our support and resources are relevant, accessible and meet needs, helping to steer our research priorities and programme activities.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

2024 WELLNESS EVENTS & FAMILY CAMPAWARENESS, INFORMATION & SUPPORT

Awareness, information & support

INFORMATION REACH

In 2025, we distributed 77,143 campaigns to existing supporters through direct mail and reached a further 48,906 prospective beneficiaries and supporters with new awareness campaigns.

We had an average campaign response rate of 13.96% across 2 streams resulting in 27,439 responses from across the country.

WEBSITE:

Total number of visits to our website in 2025 was 311,000, up 13% from 275,000 in 2024. Active users (unique) visiting the site was 185,000, up 35% on 2024.

DIABETES WELLNESS NETWORK:

Our United Through Diabetes Digital Hub received 10,569 views. Engagement on our website, such as likes, downloads, video views or link clicks, reached 1 million in 2024 which is an increase of 23% on 2024.

PATIENT INFORMATION FORUM (PiF) TICK:

As members of the Patient Information Forum, we hold PiF Tick accreditation on our adult health and social care resources. The PiF Tick kite mark is displayed on our information resources. This demonstrates that we are a ‘trusted information creator’ which is an important way in which people seeking our help can recognise that our information is relevant, up-to-date, clinically referenced and peer reviewed. We were successfully re-certified in 2025.

INFORMATION/ACCESSIBILITY:

There were 11,000 downloads from our website in 2025. We increased the volume of video content available to visitors in 2025 to ensure choice of channel and accessibility of our information. There were 1936 video views in the year, the majority of which was related to educational content via our UTD Digital Hub.

SOCIAL MEDIA CHANNELS:

Across our website and social media channels DRWF content received approx. 7.5 million views in 2025.

7

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 AWARENESS, INFORMATION & SUPPORT

Women and Diabetes Interview Series

At the heart of this project is the simple but powerful belief: every woman living with diabetes deserves to feel seen, heard and supported.

World Diabetes Day 2025 offered a fitting platform to shine a spotlight on women’s experiences in a way that is hopeful, uplifting and practical.

(Launched to coincide with World Diabetes Day (14 Nov 2025).

8 Podcast Episodes: 6 women; 1 MP, 2 Midwifes, 1 Health Coach, 1 Comedian, 1 medical technology professional.

Reach: 75,739 views on social media* News articles on drwf.org.uk read 3,323 times

*meta only

----- Start of picture text -----
Sarah Bool MP on type 1
diabetes diagnosis
Sarah said of her diagnosis: “I was
attempts to manage her condition alongside a challenging lifestyle on the completely shocked; I thought that type 1 diabetes in particular started in
road as a comedian. Laura Spence, a midwife with ADHD (attention deficit hyperactivity disorder) who experienced gestational diabetes childhood. I had no idea you could get it as an adult. I missed all the signs. I know now the 4Ts (tired, thirst, toilet, thinning) and, looking back, I can see it.
during her last pregnancy, and wants to “I started losing weight and I just
improve the experience of pregnancy, thought, oh, this is amazing. I can eat
birth and early parenthood for anything. But when I think about it, I was
neurodivergent people. ridiculously tired, and I was thirstier.
The DRWF Women and Diabetes interview series was launched with an interview with Sarah Bool MP, who is living with type 1 diabetes and sits on the All-Party Parliamentary Group on Diabetes.Also featured in the series of interviews with DRWF podcast presenter Claire Levy are: Living with Diabetes The final episode of the Women and Diabetes series features a panel including previous guests, Sajeela Kershi and Laura Spence, plus DRWF Chief Executive Sarah Tutton. They explore some of the specific challenges they have experienced.With mounting pressures on healthcare systems, peer support and lived “The signs were there. I happened to go to the doctors for something else, and they asked to do a quick blood test.“I didn’t think anything would happen, then I got a telephone call two days later saying, ‘Can you come in, because we need to run some tests. We think it could be type 2 diabetes.’ That was a surprise enough. Once they did the
Dawn Adams, a midwife living with experiences are more vital than ever. testing, I went straight to hospital and
type 1 diabetes, who experienced issues of early symptoms of menopause. World Diabetes Day 2025 offered a fitting platform to shine a spotlight on the doctors said, ‘No, this is type 1 diabetes.’
Greta Ehlers, who is living with type 1diabetes and is a big advocate for encouraging technology innovation in diabetes management to make it less intrusive. women’s experiences in a way that is hopeful, uplifting and practical. “My world flipped 100 degrees, but my family and everyone around me have been incredibly supportive. I’ve met the nicest community you can ever meet with type 1 diabetes. I feel like I’ve been
Vanessa Haydock, a body trainer and coach living with type 1 diabetes. The fifth episode of eight special programmes features a panel including supported along the way, but, oh my goodness, that was a world- changing shock because we had no family history.”
guests already featured (Dawn Adams,
Greta Ehlers and Vanessa Haydock) to
explore common issues and solutions
together about living with type 1
diabetes. living with type 1 diabetes knows that
Sajeela Kershi, who is living with type 2 this is a 24-hour condition, from the
diabetes and wants to raise awareness
in her South Asian community. Sajeela
This article was produced as part of the DRWF Living with Diabetes
podcast series.
The Women and Diabetes series
goes beyond storytelling – it is about
building connection, empathy and
hope.
DRWF:
Sarah Bool is the MP for South Sarah: “ It has its challenges. Anyone
Northamptonshire and was diagnosed
with type 1 diabetes in 2021.
144
----- End of picture text -----

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

AWARENESS, INFORMATION & SUPPORT

Autism and Diabetes Project

During 2025, the Diabetes Research and Wellness Foundation (DRWF) collaborated with Autek CIC on a project exploring the intersection between autism and diabetes. The initiative aimed to better understand the experiences of autistic and neurodivergent individuals living with diabetes and to identify opportunities to improve support, education and care.

The findings were compiled into a report which has been shared with several professional diabetes organisations across the UK. The response from the clinical community has been encouraging.

Autek CIC is a Portsmouth-based community interest company that works to improve understanding of autism and neurodiversity through lived experience research, creative engagement and accessible educational resources. The organisation specialises in developing projects that amplify the voices of neurodivergent individuals and translate those experiences into practical resources that can support both communities and professionals.

Organisations including the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society welcomed the report and recognised the importance of bringing forward the voices of people whose experiences are often underrepresented in clinical discussion.

Through this collaboration, DRWF supported a structured consultation involving autistic people with experience of type 1 diabetes, type 2 diabetes and pre-diabetes. The consultation gathered lived experiences through interviews, workshops and facilitated discussions designed to capture the realities of managing diabetes alongside neurodivergence.

The project has helped to raise awareness of the unique challenges faced by autistic individuals living with diabetes and has highlighted opportunities for improving education, communication and support.

Looking ahead to 2026, DRWF and Autek CIC aim to build on this work by developing accessible educational resources and expanding autism-friendly peer support initiatives. This will include the creation of video-based resources designed specifically to support autistic individuals in understanding and managing diabetes, alongside the development of community-based support groups.

The insights highlighted several common themes. Participants described how sensory sensitivities, communication challenges and difficulties with routine or executive functioning can affect everyday diabetes management. Many also reported barriers when engaging with healthcare services that are not always adapted for neurodivergent communication needs. Importantly, the consultation reinforced the importance of clear information, accessible education and peer support networks. Participants emphasised that personcentred approaches and supportive environments can significantly improve confidence and engagement with diabetes care.

Through continued collaboration with people living with diabetes, healthcare professionals and partner organisations, DRWF remains committed to ensuring that resources and support are inclusive, accessible and responsive to the diverse needs of the diabetes community.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 AWARENESS, INFORMATION & SUPPORT

Family Camp

Summer 2025 saw DRWF return to Whitemoor Lakes for another Family Camp collaboration with Over the Wall in support 80 campers, children, young people and families living with Type 1 Diabetes, for “a weekend of mischief and magic” from Friday 15th to Sunday 17th August.

A total of 22 families attended the DRWF Family Camp, although applications closed early on 10 March 2025 with122 completed applications received from 31 families.

----- Start of picture text -----
122
Applications 80
from 31
families campers and
22 families
attended
----- End of picture text -----

The feedback was overwhelmingly positive, with families expressing deep appreciation for the camp experience. Words like “brilliant,” “amazing,” “fun,” and “awesome” were repeated throughout.

Families valued the chance to connect, relax, and feel supported, with one adult sharing: “…With all the stress and getting used to a life with diabetes, we haven’t planned or felt able to have a holiday. You are genuinely our only break this summer. Thank you, thank you, thank you.” *

*Taken from OTW’s DRWF Family Camp Reflections Learning Report 2025

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

AWARENESS, INFORMATION & SUPPORT

Type 1 Family Camp in the Cloud

33 Families joined us

33 excited and buzzing families joined us online on Sunday, 10th December from the comfort of their own living rooms for a day of smiles, games, crafts and connection with other Type 1 families who truly “get it,” to make new friends who are on a similar journey.

*Taken from OTW’s DRWF Family Camp Reflections Learning Report 2025

----- Start of picture text -----
11
----- End of picture text -----

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

AWARENESS, INFORMATION & SUPPORT

----- Start of picture text -----
United Through
Diabetes
This year our United Through Diabetes event
looked a little bit different. As part of our
Do More with Less efforts, we moved the
event online, offering 6 new and purposeful
Webinars throughout the year which were
then added to our UTD Hub.
594 10569
registrations views in
2025
Impact: 594 registrations across the whole
UTD Programme.
–––––––––––––––––––––––––––––––––––––––––––
10569 views in 2025.
–––––––––––––––––––––––––––––––––––––––––––
Diabetes and Travelling
Trains, Planes, Boats and Automobiles
–––––––––––––––––––––––––––––––––––––––––––
NHS Type 2 Prevention Programme
NHS Type 2 Path to Remission Programme
----- End of picture text -----

–––––––––––––––––––––––––––––––––––––––––––

myDesmond

Type 2 Structured Education Programme and online self-management tool

–––––––––––––––––––––––––––––––––––––––––––

Why Should You Get Involved In Diabetes Research?

–––––––––––––––––––––––––––––––––––––––––––

Testing Times

From Tech to Tactics: Optimizing Your Bloodglucose Management

–––––––––––––––––––––––––––––––––––––––––––

Celebrate in Style

Special seasonal webinar focused on festive facts about managing diabetes and navigating those diet and party food challenges during a whole calendar of multi-cultural holidays and Festivals.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

AWARENESS, INFORMATION & SUPPORT

THANK YOU FOR SUPPORTING DRWF

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 OUR RESEARCH ADVISORY BOARD

Our Research Advisory Board

Our research advisory board comprises experts in a wide variety of research disciplines to ensure that all applications are assessed knowledgeably and fairly. As a member of the Association of Medical Research Charities, we are committed to maintaining a rigorous peer review process for the assessment of research applications, for which the Advisory Board are responsible. This process, carried out in a fair and transparent way, ensures that only the highest quality of research at the best of institutions receives DRWF funding. The Board and our review process operate within the parameters of a Conflict-of-Interest Policy which seeks to minimise the potential for conflicts to affect our decision-making process. People with diabetes are at the heart of what we do, and their views steer our wellness education programme as well as our research funding strategy.

Angela Shore, University of Exeter Medical School

Dr Mark Evans University of Cambridge

James Bowe¸ Reader in Endocrinology and Diabetes, King’s College London

Dr Kash Patel Consultant Physician in Diabetes and Endocrinology

Dr Katharine Owen Physician at the Oxford Centre for Diabetes

Professor Robert Semple University of Edinburgh

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

OUR RESEARCH ADVISORY BOARD

Susan Ozanne Professor of Developmental Endocrinology at the University of Cambridge

Professor Mirela Delibegovic Dean for Industrial Engagement in Research and Knowledge Transfer at the University of Aberdeen

Victoria Salem

Senior Clinical Lecturer in Bioengineering at Imperial College London and Honorary Consultant in Diabetes, Endocrinology and General Internal Medicine.

Professor Ketan Dhatariya Full time NHS clinician President of the Diabetes and Endocrine section of the Royal Society of Medicine.

Mr John Casey Consultant Transplant Surgeon at the Royal Infirmary of Edinburgh and Honorary Reader at the University of Edinburgh

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 RESEARCH 2025

DRWF Oxford Human Islet Isolation Facility 2025 Annual Report

Introduction

2025 was the 19th year since the opening of the DRWF Oxford Human Islet Isolation Facility. It continues to be one of the key islet isolation facilities in Europe providing clinical islets for both allo- and auto-transplantation, as well as distributing research islets for a network of basic and clinical researchers around the UK. It also continues to be active in research and development in the fields of islet isolation and islet transplantation. This report gives a brief overview of the main areas of activity during 2025.

Islet Allo-Isolation and Allo-Transplantation

Our allo-isolation programme had another successful year achieving some of our best conversion rates yet. Between January 2025 and December 2025, the DRWF Oxford Facility performed 19 clinical islet isolations for allogenic use, with a processing-to-transplant conversion rate of 63% (international average conversion is about 30%). The DRWF Facility has now provided clinical-grade islets for 119 islet transplants, and we anticipate that we will transplant our 100th local recipient during 2026. On the clinical side, we also continue to champion a patient-centric integrated beta-cell replacement model, with our satellite clinics in Birmingham and Leicester continuing to work well. As highlighted last year, the routine use of closed loop insulin delivery has meant that the traditional primary indication for Islet Transplant Alone (ITA) of life-threatening hypoglycaemia has become much less common worldwide, but nationally we have recently agreed an expansion of indications for IT to include unstable glycaemia. We anticipate that this will increase referrals for IT again over coming years. Our most common indication for islet transplantation remains Simultaneous-Islet-Kidney transplant for those people where whole pancreas transplantation is contraindicated. This is an excellent procedure that aims to protect the transplanted kidney from ongoing damage from diabetes and adds little additional procedural risk to the patient than the kidney transplant itself. We also have patients on our waiting list for Islet After Kidney transplantation.

Facility isolation staff. Referrals for TPIAT in children continue to increase and based on our experience of undertaking a few successful TPIATs in the under 18 age group, we have applied for NHS-commissioning to be able to routinely undertake TPIAT in children, something that the combined adult and pediatric expertise in Oxford makes us ideally placed to do. The TPIAT programme in Minneapolis has demonstrated the significant advantages in terms of diabetes outcomes if, once chronic pancreatitis is established, the TPIAT is performed in childhood rather than delayed until adulthood.

Research Islet Provision

The DRWF Isolation Facility in Oxford continues to be the UK Islet Resource Centre providing quality human islets for research to a network of type 1 and type 2 diabetes researchers. This is a rare and important resource and the DRWF Oxford Isolation Facility is central to this. During 2025, we distributed over 1 million islet equivalents (IQ is the international standardised way of counting islets) to such researchers. In addition, the Oxford DRWF Islet Isolation team continue to play a key role in the ‘Islet Platform’ for the related Quality in Organ Donation (QUOD) with responsibility for isolating and distributing islets for research from these rare pancreases. We are also part of two collaborative research projects under the Diabetes UK Type 1 Diabetes Grand Challenge, something that we believe is of enormous benent to DRWF within the current landscape of diabetes research in the UK.

Islet Auto-transplantation

We continue to have a very active NHS-Commissioned programme for Total Pancreatectomy with Islet Autotransplantation (TPIAT) and the DRWF Islet Isolation Facility is a key part of this programme. These patients are undergoing total pancreatectomy for chronic pancreatitis, and we extract the islets from the resected pancreas (discarding the diseased pancreatic exocrine tissue) and reinfuse these islets back into the patient before the end of their operation. During 2025, the DRWF Islet Isolation Facility performed 6 clinical islet isolations from such pancreases, and all these preparations were transplanted back. These chronically scarred pancreases are inherently difficult to extract islets from, but the team have achieved impressive islet yields from these resected organs, a testmony to the experience and skills of the DRWF

Vertex Stem-Cell Derived Islet Trials

As stated in our previous report, Oxford was opened as the first site in the UK for the Vertex 880 (stem-cell derived islets with immunosuppression) and Vertex 264 (stem-cell derived islets placed in capsules and transplanted without immunosuppression) clinical trials. The 264 has now stopped recruiting, but the 880 continues to recruit patients. The published data from the 880 Trial have been impressive and demonstrates good function from these islets. The role that the Oxford DRWF Facility team are playing a in these landmark studies again demonstrates the wider impact and recognition that DRWF are having within the islet transplant field internationally.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

RESEARCH 2025

DRWF Islet Facility Staff

I remain Director of the Facility and the facility’s Designated Individual for the HTA. During 2025, we appointed an excellent new Deputy-Facility Manager, Artjoms (Art) Portnojs. Art works extremely well with our Facility Manager. Rebecca Spiers, and the two of them manage all aspects of the actual islet isolations, plus lead on the HTA regulatory side of our Facility and Programme as Person Designated. Louise Stile as our Facility Administrator / Coordinator, continues to play the critical role of coordinating every aspect of the DRWF Facility including the islet isolation team and the clinical and research aspects of the islet isolation programme. She also manages our regular MDT, Facility, and Research meetings and is our main contact for all collaborations and external liaisons with the DRWF Islet Isolation Group. I remain indebted to each one of these DRWF-funded staff members for their essential contributions and to DRWF for their ongoing staff funding which we couldn’t function without.

The DRWF Facility

Our Facility will be 20 years old next year. It remains the only purpose- built clinical islet isolation Facility in the UK and continues to function at the highest HTA standards, as evidenced by our monthly monitoring. We will be due our routine biennial HT inspection during 2026. We continue to welcome anyone connected to DRWF who would like to visit the Facility, and continue to be visited by staff from other centres around the world as part of our ongoing support and training within the islet field.

Islet Research

Our Isolation Group continue to be research active with a guid-pro-guo arrangement between the University and NHS. Our research interests continue to focus on optimisation of islet isolation with particular emphasis on the pancreatic matrix and islet immune protection with the ultimate aim of transplanting islets into children without the need for immunosuppression. We have recently appointed a senior postdoctoral scientist whose research focus is the neogeneration of islets from the pancreatic exocrine tissue that is usually discarded during islet isolation. He has a strong track record in this field and the plan is to expand this exciting project.

New Initiatives

At the end of 2025, it was announced that The Bukhman Foundation has gifted £10 million to the University of Oxford to establish the Bukhman Centre for Research Excellence in type 1 Diabetes. This new initiative is a major coup for Oxford and means that T1D will be prioritised increasingly by our University. The Bukhman Centre has 3 main themes, one of which is Cell Therapy, and I will be leading that theme. The DRWF Facility and Isolation team were a key part of the application and award of this new initiative and will remain key to this new initiative moving forward. In addition, we are part of a new EU collaborative grant application which involves all the main islet centres in Europe. Finally, in January 2027, I will take over as President of the European Pancreas and Islet Transplantation Association (EPITA) and I look forward to continuing to develop the collaboration of EPITA and DRWF.

In closing, I would like to reiterate my immense gratitude to the DRWF Trustees once again for their ongoing generosity in funding the Oxford Programme, and to reiterate my team’s commitment to maintain our close and successful partnership with DRWF for many years to come. We will continue to champion the wonderful work of DRWF in every way we can.

Professor Paul Johnson Director Oxford DRWF Human Islet Isolation Facility

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 RESEARCH 2025

Sutherland-Earl Clinical Fellowship 2025

Sutherland-Earl Clinical Fellowship 2025

Dr Rama Gnanakumar from the University of Cambridge was awarded the Sutherland-Earl Clinical Fellowship 2025.

The award is for a total of 3 years and begins in August 2026.

Title: Fully closed-loop insulin delivery in young-onset type 2 diabetes: Assessing impacts on glycaemic outcomes and qualityof-life in a diverse population

Lay summary: Increasing numbers of people under the age of 40 are being diagnosed with type 2 diabetes (T2D), especially those from ethnic minority and/or more disadvantaged backgrounds. Keeping blood sugar (glucose) levels in the target range reduces the risk of serious health problems but can be challenging. This research will look at whether an automated insulin delivery system, which includes an insulin pump and a glucose sensor, can help people with T2D requiring insulin treatment to better control their glucose levels.

We will study how this technology affects people aged 18 to 39 with T2D, making sure to include people from ethnic minority and more deprived backgrounds. Those taking part will spend three months using the automated insulin delivery system and three months using their usual insulin with a glucose sensor, in a random order. In addition to comparing glucose outcomes we will look at whether the technology can improve quality-of-life.

£248,410.24

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

RESEARCH 2025

DRWF Funded Researcher aids in evaluation of the safety and efficacy of hybrid closed loop (HCL) use during the first six months of pregnancy.

A new report has found that using HCL during pregnancy and after birth could be more beneficial for mothers with type 1 diabetes, over standard insulin delivering, in controlling glucose levels.

Most pregnant women with type 1 diabetes do not have glucose levels in the pregnancy-specific glucose target range, which may have negative consequences for the offspring.

Among non-pregnant adults and children, use of HCL insulin therapy has been associated with improved glucose control, but whether it can achieve more stringent glucose targets required for optimal pregnancy outcomes was previously unknown.

Researchers said: “Clinical guidelines in the UK and elsewhere do not specifically address HCL use in the postpartum period when the demands of caring for a newborn are paramount. Our aim was to evaluate the safety and efficacy of HCL use during the first six months postpartum compared with standard care.”

The study of 124 pregnant women with type 1 diabetes was held at various locations in the UK.

Study participants were randomly assigned to receive HCL therapy or standard insulin therapy and continuous glucose monitoring.

In early tests, the primary outcome was the percentage of time in the pregnancy-specific target glucose range (63 to 140 mg per decilitre) from 16 weeks’ gestation until delivery.

A recently published report in The Lancet Diabetes & Endocrinology details the findings of an extension to an earlier trial – Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study.

additional 3-6 hours a day, compared with those assigned to CGM alongside standard care insulin delivery. Glycaemic improvements were met by a marked reduction in maternal hyperglycaemia, especially evident overnight, and the improvements were not accompanied by an increase in hypoglycaemia.

Researchers said: “Pregnant women with type 1 diabetes at nine UK sites were followed up for six months postpartum.”

The postnatal extension trial ran from 12 November 2021 to 4 May 2023.

“In this study, although breastfeeding rates were initially low in the HCL group they were similar in both groups by six months postpartum, and comparable to national breastfeeding rates in the general maternity population, where prevalence of any breastfeeding is 55% at six weeks postpartum and 34% at six months postpartum.”

Detailing the study, researchers said: “Out of the 124 trial participants, 66 (53%) were not eligible for inclusion in the postpartum extension study, with 60 (91%) participants over six months postpartum and six (9%) participants who had discontinued HCL or control interventions (standard insulin with CGM) within the first six months. One participant in the control group had a neonatal death and the investigators considered it inappropriate to approach her about the extension study.”

Researchers concluded: “The AiDAPT trial established the efficacy of HCL therapy during type 1 diabetes pregnancy with glycaemic benefits over and above CGM with standard insulin therapy. Our current findings support continued use of HCL from pregnancy into the postpartum period. Clinical benefits are sustained throughout the first six months postpartum compared to a marked deterioration in glycaemic control with CGM and standard insulin delivery.”

Researchers found that “women continuing HCL from pregnancy into the postpartum period spent 15% more time within the non-pregnancy glucose target range, an

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

RESEARCH 2025

How a rare form of childhood diabetes is shedding light on beta cells – and the future of diabetes care.

Imagine being told your newborn baby has diabetes. For a small number of families, this is a heartbreaking reality.

However, in some cases, the diabetes disappears within a few months – only to potentially return years later. This rare form of the condition is known as transient neonatal diabetes mellitus (TNDM) and, in a major step forward in diabetes research, it is offering scientists unexpected new insights into how insulinproducing cells develop and function – and what might go wrong in all forms of diabetes.

Thanks to funding from DRWF, a new study led by James Russ-Silsby and his team at the University of Exeter has discovered a brand-new genetic cause of TNDM. Their findings, now under review at a leading scientific journal, shed light not only on this rare condition but also on the fundamental biology of diabetes itself.

This is the first new gene to be linked to TNDM in over a decade – and what it is revealing about the development of insulin-producing beta cells could have far-reaching implications for diabetes research and treatment.

What is transient neonatal diabetes mellitus?

Neonatal diabetes is a condition where diabetes appears in the first six months of life. Unlike type 1 diabetes, which is caused by the immune system attacking insulin-producing cells, neonatal diabetes is almost always genetic. In about half of cases, the diabetes is transient, meaning it goes away after a few months. However, it can return later in childhood or adulthood.

The rarity of the condition makes it difficult to study, but understanding the genetic causes of neonatal diabetes can unlock vital clues about how insulin production works – and what can go wrong. This is why James’s research has been so exciting.

The breakthrough a decade in the making

Until now, only eight genes had been linked to transient neonatal diabetes.

Most were discovered more than 10 years ago, and in recent years progress had slowed. But the Exeter research team has now identified a ninth gene, called PAX4, as a previously unknown cause of the condition.

The breakthrough came after genome sequencing was performed on 18 children with TNDM and their parents, creating a detailed map of the genetic information passed down in each family. In two unrelated families, the researchers found “spelling mistakes” (or mutations) in both copies of the PAX4 gene – mutations that completely shut the gene down.

Previous studies in test models had already shown that deleting PAX4 leads to a complete loss of pancreatic beta cells and a corresponding increase in alpha cells, which produce glucagon.

However, until now, there had been no confirmed reports of people born without functioning PAX4 genes. The discovery of two unrelated children with this exact genetic change provided the first clear human evidence of PAX4’s essential role in the development of insulin-producing cells.

What the discovery tells us

What is especially intriguing is that despite losing PAX4, these children still managed to develop some insulin-producing beta cells – enough for their diabetes to be temporary. It suggests that, in humans, the total loss of PAX4 does not entirely prevent the development of beta cells, unlike in test models. This difference offers new insight into the unique ways in which human beta cells form and mature – and may help explain why diabetes takes different forms in different people.

To dig deeper, the Exeter team collaborated with experts at the Translational Genomics of Diabetes Lab at Stanford University in California, US to look at what PAX4 does in lab-grown beta

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

RESEARCH 2025

cells. Using a technique called CUT&RUN sequencing, they mapped out the DNA regions controlled by PAX4 in these cells.

They found that the gene acts as a kind of master controller, regulating other genes that are essential for beta cell development and for releasing insulin in response to sugar in the blood. In short, PAX4 is critical not just for making beta cells, but for helping them function properly – making it hugely relevant to understanding all forms of diabetes.

How this helps real families

For the two children identified in the study, this research has already had direct benefits. They now have a clear genetic diagnosis – something that can be crucial for planning future treatment, monitoring for recurrence, and offering reassurance and information to families.

It also means that PAX4 can now be added to genetic testing panels used to diagnose neonatal diabetes. This will help identify other children with this rare subtype, giving them and their families access to early diagnosis, and more targeted monitoring and treatment later in life.

Beyond diagnosis, the discovery also offers long-term potential for improving diabetes therapies. By revealing how PAX4 helps build and regulate beta cells, the research adds to the growing body of knowledge that underpins efforts to regenerate or replace these cells in people with diabetes. For example, stem cell therapies aimed at creating new beta cells could be improved by better understanding how genes like PAX4 shape their development.

A second genetic clue: A shared mystery region

In addition to the PAX4 discovery, the team also identified a mysterious shared stretch of DNA in three families with neonatal diabetes – a “haplotype” on chromosome 19 not found in public databases. While they have not yet pinpointed the exact gene responsible, it is highly likely that this region contains another undiscovered cause of neonatal diabetes, and the team is already applying for funding to continue this search.

Meanwhile, the PAX4 work has been submitted for publication and recently shared at major diabetes conferences, including the 2024 EASD Minkowski Award Lecture and the 2025 Diabetes UK Professional Conference. This ensures the findings are reaching both the scientific community and the public – and highlights the importance of continued investment in rare disease research.

Looking ahead

The work conducted by James and his colleagues not only met the goals set out at the beginning of the research programme – it exceeded them. As well as identifying PAX4 as a novel cause of TNDM and mapping its role in beta cell development, the team has laid the groundwork for future discoveries and diagnostic improvements.

The findings have already been shared with the scientific community through presentations at major conferences, and a paper describing the work has been submitted to the journal Molecular Metabolism. A preprint version is available online, making the results immediately accessible to researchers worldwide.

While this study focused on a rare condition, its impact extends far beyond the few families affected. By helping to unlock the secrets of beta cell formation, this research contributes to a broader understanding of diabetes and brings us one step closer to better treatments.

This study may have started with a handful of rare cases – but it is ending with insights that could benefit millions.

By uncovering a new gene involved in insulin production, James’s team is helping to rewrite our understanding of how diabetes begins, and how it might one day be stopped.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

COMMUNITY FUNDRAISING IN 2025

5 Schools

1,645 Pupils took part

2022

2023

10 Schools 2,839 Pupils took part

----- Start of picture text -----
Y
40%
SCHOOL 60%
DRWF
GOES TO YOUR
GOES TO
HOW OURD
O
N
A
TIO
N
IS
S
P
TIL
----- End of picture text -----

Since 2022, over £30,000 has been given back to the schools involved in the program, allowing it to be spent on whatever they need. Our pledge is to: SHARE 40P OF EVERY £1 RAISED IN EACH SCHOOL.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

COMMUNITY FUNDRAISING IN 2025

----- Start of picture text -----
15
Schools
4,431
Pupils took part
2024
18
Schools 2025
5,585 Get your school moving!
Pupils took part
is now
UK WIDE!
Raised
in 2025
£3,361+
Taking part in the Dance for Diabetes fundraiser was an
incredible experience for our whole school community. From
Year R to Year 6, every child got involved – and loved every minute
of it! The event was brilliantly organised with all resources provided,
making it easy and flexible for staff to get on board. It was fantastic
to see every member of staff taking part and parents coming along to
cheer the children on. Most importantly, it was great fun and brought
the whole school together for a fantastic cause. We were thrilled to
raise thousands of pounds – a huge success all round!
Mrs Z Simpson
Class Teacher,
Otterbourne Church of England Primary School.
2026
----- End of picture text -----

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 COMMUNITY FUNDRAISING IN 2025

Diabetes Dawdle 2025 Summary

Registered Dawdlers: 80 (79 Portsmouth, 1 Virtual) Raised: £4,282.51

Comment from Tim Green, Head of Community Fundraising:

I am delighted by the continued growth of the Diabetes Dawdle in 2025, with fantastic increases in both participation and income. This year, 80 walkers took part, raising an event record.

----- Start of picture text -----
RAISED
OVER
£4,282
----- End of picture text -----

Blessed with beautiful weather, the picturesque South Coast shoreline became a sea of red as we came together to dawdle in support of people living with diabetes and the families who support them every day. Families enjoyed a wonderful community day out, with opportunities to talk, smile and even enjoy a drink and ice cream, before returning to where it all began at The Spice Island Pub in Old Portsmouth. It was a fantastic event that truly captured the sense of community, togetherness and shared purpose that sits at the heart of our work.

Comments from London Marathon 2025:

“9 days before my 9th birthday this year in May my life changed forever! I was diagnosed with Type 1 diabetes and was rushed to hospital with DKA. I will be walking 7 miles with my family to raise money and awareness” Maxwell Blaker, Diabetes Dawdle Portsmouth 2025 Raised £182

“My big brother Maxwell got diagnosed with Type 1 diabetes in May this year so I will be walking 7 miles for him and all the other diabetes heroes”

Eloise Blaker, Diabetes Dawdle Portsmouth 2025

Raised £50

Entire Blaker Family raised £1,213.51 during this event. I’m doing this because on November 27th 2024, our world was flipped upside down when our 2 year old was diagnosed with type1 diabetes, during a week long stay on the children’s ward in hospital. (After what I suspected was a water infection). Life

has been extremely tough ever since; numerous Hospital visits, infections, failed pumps, failed pods, counting CARBS in everything she eats, NUMEROUS alarms going off at all hours. Emotions have been all over. Our world as we knew it was swiped from under our feet and it became so small.

Harper has been through more in 6 months than some people might go through, ever. It has been extremely tough, yet she’s taken every single thing in her stride. She has been an absolute warrior.

Some people, myself (previously) included, think “it’s manageable”, however, they don’t see the 3.am panic, the wake-ups to manage the highs and the lows, the daily tears because of the worry about the huge implications this has if we don’t “get it right”. I wish we could share this weight, just so others could know how heavy it really is.

Every donation helps support people living with all types of diabetes, and funds research into better treatments and, one day, a cure

Laura Harrison, Diabetes Dawdle Portsmouth 2025 Raised £315

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

COMMUNITY FUNDRAISING IN 2025

Cardiff Half Marathon 2025 Summary

Registered Runners: 41, (29 Charity Places, 12 Own Place) Raised: £11,639

Comment from Tim Green, Head of Community Fundraising:

----- Start of picture text -----
RAISED
OVER
£11,600
----- End of picture text -----

Our team at the Cardiff Half Marathon 2025 delivered a fantastic performance, with 41 runners raising an impressive £11,639 to support people living with diabetes.

We are incredibly grateful for the commitment, determination and generosity shown by everyone involved. Their efforts made a meaningful contribution and reflected the strength of our fundraising community.

We look forward to building on this success and growing an even larger team in the year ahead.

Comments from Cardiff Half Marathon:

“I’ll be Fundraising for Diabetes Research and Wellness Foundation in the Cardiff half marathon because this is deeply personal to me - my dad lives with type1 diabetes. Watching him manage the daily challenges of the condition gave me first hand understanding of how life altering it can be. Despite the obstacles, he faces it with strength, and his journey inspired me to take action. By running this half marathon, I hope to raise both awareness and funds to support ongoing research, improve treatments and move closer to finding a cure for the millions affected by diabetes every day.

Mia Debattista, Cardiff Half Marathon 2025 Raised £465.00 Signed up for 2026 to represent DRWF again.

I’m running the Cardiff Half Marathon to raise money for the Diabetes Research and Wellness Foundation (DRWF), a cause very close to my heart. Diabetes affects millions of people in the UK, including some of my own family and friends. I’ve seen firsthand the challenges it brings to daily life, as well as the importance of research, education, and support in helping people live well with the condition.

By taking on this half marathon, I want to do my part to support the incredible work of DRWF. The funds raised will go towards vital research and resources to help improve lives and move us closer to better treatments, and hopefully, one day, a cure.

Lucie Fernes, Cardiff Half Marathon Raised £570.00

I’m running the Cardiff Half Marathon to raise money for a cause that means a lot to me - Type 1 Diabetes. My fiancé Maddie, lives with type 1, so it’s something I see the impact of every single day. It’s not just the managing blood levels or insulin injections — it’s the constant balancing act, the sleepless nights, and the mental load that never really goes away. Supporting someone you love through that changes how you see things. It’s made me want to do something positive — to help fund better treatments, raise awareness, and support others going through the same.

Gareth Hodgson, Cardiff Half Marathon 2025 Raised £385.00

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 COMMUNITY FUNDRAISING IN 2025

London Landmarks 2025 Summary

RAISED OVER £4,783

Registered Runners: 11, (9 Charity Places, 2 Own Place) Raised: £4,783.99

Comment from Tim Green, Head of Community Fundraising:

The London Landmarks Half Marathon, one of the most popular and vibrant events in the running calendar, offers participants the opportunity to pass some of the capital’s most iconic landmarks while supporting causes close to their hearts.

In 2025, we were proudly represented by 11 runners who collectively raised an impressive £4,784 in support of people living with diabetes. Through early morning training runs in all conditions, including rain and snow, the team demonstrated real grit, determination and resilience in taking on this challenge.

They were a fantastic group to support throughout their journey, and we are incredibly grateful for their commitment and enthusiasm.

Over the Christmas period in 2020 I was suddenly losing weight and finding myself needing to go to the toilet in the night. Little did I know these are signs to my diagnosis of Type 1 diabetes. I was 32 years old and had no idea what this whole process would mean. Since being diagnosed I have a much better understanding and have figured out a good way of dealing with my levels and insulin intake. A year after my diagnosis I found out I also had coeliac disease which can come hand in hand with diabetes.

Comments from London Landmarks Half Marathon: I was diagnosed with Type 1 diabetes at the age of 13, 39 years ago. It’s never stopped me doing much. 3 years ago I started couch to 5 km. since then there’s been plenty of 5km runs, lots of 10km runs and Few half marathons. 18 Months ago I completed 3 halfs in 5 weeks, This year I’ll be completing 3 halfs in 8 weeks. Cardiff Winter warmer run, Bath Half marathon and London Landmarks all for diabetes research.

Yoan Jones, London Landmarks Half Marathon 2025 Raised £610

I will be running this half marathon for my grandad George, my favourite childhood memories all consist of being with him hiking and exploring the Scottish hills, he was always up front telling us to keep up and to keep a look out for the wild haggis. He showed me some of the most incredible lochs and picturesque views which are memories I will cherish forever. I will be doing this run for him in his memory while raising money for diabetes research.

Laura Bryson, London Landmarks Half Marathon 2025 Raised £680

I have decided to run the landmarks half marathon and raise money for a great cause. Please donate and help me raise awareness for Diabetes Research & Wellness Foundation.

Michael Phillip, London Landmarks Half Marathon 2025 Raised £425

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

COMMUNITY FUNDRAISING IN 2025

London Marathon 2025 Summary

Registered Runners: 2 (1 Charity Place, 1 Own Place) Raised: £6,146

Comment from Tim Green, Head of Community Fundraising:

The London Marathon, one of the most prestigious running events in the world, once again provided an incredible platform to raise awareness and vital funds in 2025.

----- Start of picture text -----
RAISED
OVER
£6,146
----- End of picture text -----

We were proudly represented by two runners, John and Chloe, who together raised £6,146 in support of people living with diabetes. John ran as our charity place participant, taking on the challenge in support of his brother, who lives with type 1 diabetes. Chloe ran in memory of her late mother, making her participation especially meaningful and inspiring.

We are extremely grateful to both John and Chloe for their commitment, passion and support

Comments from London Marathon 2025:

Why am I running the London Marathon 2025?

It all started with my little brother Simon, being diagnosed with Type 1 Diabetes in 1975 at the age of 9. As a family we knew nothing about Diabetes and there was very little information available in the mid-70’s.

Whilst Insulin was available at that time as a family we helped Simon to accept his condition and we educated ourselves in the dietary and exercise requirements to support our brother in managing his medication and the changes that were needed to be made to keep Simon safe and encourage him to talk about his condition. At the time we didn’t know what Simon’s life expectancy would be.

Simon is now 58 years old and very fit and healthy, runs marathons himself and I am inspired by Simon - and running the London Marathon 2025 to raise money for the Diabetes Research and Wellness Foundation, towards their ultimate goal to discover a cure.

Over the years other family member and friends have also been diagnosed with Diabetes, Dave my Father In Law, and my best mate (end Best Man), Ian Hunter, all relying on the fantastic work done by the Diabetes Research and Wellness Foundation.

John Gillibrand, London Marathon 2025 Raised £5,736.00

----- Start of picture text -----
27
----- End of picture text -----

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 CHARITABLE TRUSTS & LEGACIES RECEIVED

2025 Charitable Trusts and Grants Received

We are very grateful to the charitable trusts and foundations who have so generously invested in the DRWF, facilitating the expansion and continued development of our education and research programmes.

A gift of hope

Leaving a gift in your Will, is to leave a gift of hope for future generations. Legacies are vital to every charity as they provide the bedrock financial support that we rely upon to look ahead. A legacy bequest to DRWF enables us to continue supporting world-class research whilst the educational programmes that we provide ensure that people with diabetes are ‘staying well until a cure is found…’

A legacy to DRWF is an investment in a brighter future for people with diabetes. We would like to share out gratitude to the following people, who left Legacies to us in 2025:

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

GIVING IN MEMORY

Giving in memory of a loved one

In memory giving is a special way of remembering a loved one, and the causes that were important to them. We are honoured to be nominated to benefit from donations after a person passes away.

Donations given in memory are a positive way of celebrating life which helps us to continue funding the research and educational programmes that improve quality of life for people with diabetes. In partnership with ‘Much Loved’, the memorial tribute charity, you can set up a tribute page in memory of a loved one which can be shared with family and friends – www.drwf.org.uk/getinvolved/giving-in-memory.

In 2025, we received gifts in memory of the following –

Our work is made possible only through our supporters’ commitment and generosity, for which we say a heartfelt THANK YOU!

27

29

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 HOW TO SUPORT DRWF

Your support makes all the difference

YOUR GENEROSITY HELPS DREAMS BECOME A REALITY!

Alarmingly, diabetes continues to grow in pandemic proportions around the world and with more than 5.8 million people now living with diabetes in the UK, our work is increasingly important.

Did you know that individual donations and legacies make up much of our income?

Your gifts enable us to fund vital awareness campaigns, and educational programmes that support self-management of diabetes, whilst the research we fund seeks to improve understanding, treatment, management and cure of diabetes.

Contact us and get involved

YOU can do any one of these things and so much more to support our work. We are investing in a brighter future for people with diabetes, WILL YOU

Visit our website and see how you can GET INVOLVED https://www.drwf.org.uk/get-involved/

Email enquiries@drwf.org.uk to request further information OR Call us on 023 9263 7808

Will you make a difference? You could -

Become a volunteer supporting the delivery of our campaigns and Wellness educational events – we are a small team and volunteer help is vital to ensure we can deliver our award-winning activities across the country.

VOLUNTEER

Make a regular donation by direct debit to support all our work by becoming a Partner for the Cure – regular giving means that we can plan effectively for future activities and more of your donation goes straight to the cause!

DONATE

Play our lottery. This is a great way to support our work whilst having the opportunity to win a cash prize – you can sign up to play online by monthly direct debit.

PLAY OUR LOTTERY

You can take part in numerous thrilling events throughout the year, across the country, putting the FUN into fundraising! This is a great way to get actively involved in supporting the charity, creating awareness and funds to support the cause.

FUNDRAISE

GIVE A GIFT OF HOPE

Leaving a gift in your Will, is a powerful and easy way of supporting our work and leaving a legacy for future generations. A significant percentage of our income each year comes through legacy bequests. It’s surprisingly simple to set up and supports our commitment to multi-year research projects that might just generate the next big breakthrough.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FUTURE PLANS

Our focus in 2026 and beyond

Our focus for 2026 is very much on ensuring that we have the necessary funds to build a resilient and sustainable organisation that can meet the ongoing, and ever-changing, needs of our beneficiaries.

Whilst we recognise that the charity sector continues to be a challenging space, industry reports do offer some little nuggets of hope. Take up of mass participation events and community fundraising activities appear to be on the increase especially with younger people, a community that we are working hard to reach. At the end of 2024 we secured a debenture for 20 TCS London Marathon places for the next 4 years. This was a big win for our small community fundraising team of 2 who are intent on maximising this opportunity alongside a growing schedule of home-grown and third-party activities.

With investment in individual and sustainable giving programmes, as well as a focus on securing appropriate partnerships and sponsorships, we are intent on reversing the negative impact that both the pandemic and the economic climate have had on our ability to diversify and develop our fundraising portfolio and ultimately deliver Research and Wellness programmes that meet the needs of the diabetes community today and in the future.

To do this effectively, we plan to –

----- Start of picture text -----
31
----- End of picture text -----

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 CHARITY INFORMATION & GOVERNANCE

Reference and Administrative Details

Charity Number: 1070607
Company number: 03496304
Registered Ofce: Building 1000 Langstone Park
Havant, Hampshire
PO9 1SA
Tel: 023 92 637808
Website: drwf.org.uk
Trustees & Directors: Mr John Alahouzos (Chairman)
Mr Steve Jones
Mr Christian Gretschel
Mr Adrian Durelli
Mr Arez Salim
Mr Mike Arenas
Chief Executive: Mrs Sarah Tutton
Advisers
Bankers: Barclays Bank Plc
1 Churchill Place
London E14 5HP
Solicitors: Blake Morgan LLP
New Kings Court
Tollgate
Chandlers Ford
Eastleigh SO53 3LG
Secretary: Blake Morgan Company
Secretary Services
Auditors: Moore Kingston Smith LLP
6th Floor, 9 Appold Street
London
EC2A 2AP

32

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

CHARITY INFORMATION & GOVERNANCE

Structure, Governance & Management

Governing Document - The Diabetes Research and Wellness Foundation, also known as DRWF, is a registered charitable company (Registered Charity No. 1070607 and Company No 03496304) limited by guarantee and governed by its Memorandum and Articles of Association dated 15 January 1998 and amended by special resolutions passed on 15th June 1998, 2nd December 2001 and 24th April 2005.

Recruitment & Appointment of Trustees - The charity trustees are also the directors of the company for the purposes of company law.

As dictated by the charity’s Articles of Association, directors are appointed by the Company Members. Any person desiring to be admitted to the membership of the company is required to apply in writing. No person shall be admitted until approved by resolution passed in accordance with the Articles of Association by the existing members, who hold absolute discretion as to the admission of any person.

The Trustees of the charity, being mindful that the board should offer a diversity of skills to fulfil statutory and fiduciary duties, are open to recommendations for new board members.

The business and medical/health related skills within the existing board member pool are supported by personal experience of diabetes, which assists the board in ensuring that objective activities meet beneficiary need.

Additionally, the board is supported in its decisionmaking processes by a Research Advisory Board, which has an independent Chairman. The RAB members review applications and make recommendation for research funding awards. An Editorial Advisory Board provides support to the provision of health and social care information. Both boards are made up of clinicians, scientists and other ‘experts’ in the field of diabetes and related health and strengthen the services that the charity offers its beneficiaries.

All board members are subject to ‘conflict of interest’ policies and processes.

Trustee Induction and Training – Newly elected Trustees receive an Induction Pack that outlines the role and responsibilities of the Trustee, along with a history of the structure and purpose of the charity.

The pack includes a copy of the governing document and contact details of all board members. There is also an outline of the Chairman of the Board’s role and responsibilities along with details of the executive officer taking responsibility for the daily management of the charity. Trustees are required to comply with the eligibility requirements set out by Charity Commission and to review and update an annual Register of Interests.

Trustees are kept up to date with various governance publications and notices from appropriate professional advisory memberships. Additionally, trustees might be advised of appropriate governance courses that they may benefit from attending to ensure diversity and continuity of knowledge and skills within the Board.

Newly elected trustees are invited to attend a Review Meeting with the chair, after an agreed time lapse, to feedback their first impressions and address any concerns. Trustees are actively encouraged to participate in the charity’s outreach programme of educational events.

Governance - The strategic direction and policy of the charity is the responsibility of the Board of Trustees. The Board is aware of the revised Charity Governance Code and use this guidance to support discussions about standards, behaviours and processes. At the start of 2025 four trustees served on the Board, from a variety of professional backgrounds relevant to the work of the charity. The Board meets routinely throughout the year post-quarter end to review activities and management accounts. Additional meetings are organised as required. Since the Covid-19 pandemic all meetings are held virtually.

The Chief Executive carries out the daily operations of the charity and is responsible to the Board of Trustees.

Connected & Related Parties – DRWF co-operates on several intellectual matters including sharing articles and reports with the Diabetes Research and Wellness Foundation Inc., a 501C3 Not for Profit Company operating in the United States; Association pour la recherche sur le diabete (A-rd) in France; Insamlingsstiftelsen Diabetes Wellness Network Sverige (Sweden); Diabetes Wellness Suomi (Finland) and Diabetes Wellness Norge (Norway). These organisations are completely autonomous and independent with no legal connections.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 CHARITY INFORMATION & GOVERNANCE

Links between these independent organisations, has proved invaluable to the charity in helping to strengthen it’s international presence, for the purpose of supporting diabetes research programmes and global awareness activities.

A Register of Interests for Board Members and Key Management Personnel is maintained and reviewed on an annual basis.

Remuneration Policy for senior staff - The Trustees, who are also the directors, and the Chief Executive Officer comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day-to-day basis.

All trustees give their time freely and no trustee received remuneration in the year. Details of trustees’ expenses are disclosed in note 12 to the accounts. Related party transactions are disclosed in note 20 to the accounts.

The salary of all staff, including the chief executive officer, is reviewed annually and normally increased in accordance with average earnings. In view of the nature of the charity, its size and structure, the trustees undertake a benchmarking exercise, using online research/tools, comparing the charity’s salaries against pay levels offered for similar roles within other charities and companies.

The benchmark is the mid-point of the range paid for these similar roles with consideration given to workload, level of responsibility, anticipated rate of inflation and other published research on third sector rates of pay.

The charity considers that its remuneration policy:

Volunteers – As a small team delivering numerous activities, we rely on the support of volunteers who participate by helping with administrative tasks in our office; delivering diabetes awareness and information materials; undertake user involvement exercises to help steer and develop our programme activities; support our educational events and community fundraising programme or sit on one of our expert panels for research or information review. The number of volunteers fluctuates each year but is crucial to helping us spread the word about the work we do and to support local and national community initiatives.

In addition to our Trustees, we have an Editorial Advisory Board and a Research Advisory Board. These are panels of diabetes clinicians and scientists, and other relevant professionals and lay people, all of whom offer their time and expertise voluntarily to ensure that we meet the high standards required of us through our Association of Medical Research Charities (AMRC) membership and our commitment to producing clinically evidenced health and social care information in line with our PiF accreditation. We wholeheartedly thank all our volunteers for their time, expertise and commitment which helps us raise awareness to the charity, maximise income and maintain high standards of work.

Risk Management – The Trustees have examined the major strategic, business, reputational and operational risks that the charity faces. This involves identifying specific risks; assessing their likelihood of occurrence and potential impact; determining what steps could be taken to mitigate those risks and delegating responsibility to key staff for overseeing management of the associated controls. The risk register is reviewed annually to ensure the adequacy of internal control mechanisms.

Our approach to risk assessment and management is evidenced across the organisation and throughout our activities. The risk register was circulated to the Trustees for review and scoring in November and resulting risks discussed at a Board meeting held on 22nd December.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

CHARITY INFORMATION & GOVERNANCE

The Board considers that the major risks facing the charity at present, are –

Medium:

High:

The charity operates in an increasingly challenging and competitive fundraising environment, with traditional income streams experiencing volatility and greater pressure from rising costs of living and increased competition for grants and corporate support. Legacy income also remains a significant but inherently unpredictable funding source.

To mitigate the risks associated with fluctuating income, the charity is actively diversifying its fundraising activities to reduce reliance on any single or unpredictable stream, broaden its reach to new supporters and beneficiaries, and offer more varied engagement opportunities.

We recognise that income instability could affect our ability to deliver charitable activities, so we continue to adopt an agile approach to safeguarding our aims and objectives. All new projects and activities are carefully assessed to ensure alignment with our charitable purpose, organisational powers, and any relevant restricted funding requirements. This diligence is especially important as we evolve our work to remain relevant to the diabetes community while strengthening partnerships that support sustainable long term impact.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 CHARITY INFORMATION & GOVERNANCE

Complaints

The charity has a published complaints procedure, available on its website, and endeavours to respond to enquiries and complaints within the stated timeframe. Most contacts tend to be a request to opt-out of charity communications by existing supporters and we monitor the basis on which people request this i.e., content of appeal, volume of contact, type of contact, method of contact to inform our campaigns with the aim of reducing any perception of unreasonable intrusion, persistent approach or undue pressure to support. We didn’t receive any complaints about our fundraising practices during the year.

Fundraising Policy

The trustees are aware of their responsibilities and accountabilities to ensure that the charity fundraises legally, responsibly and effectively. The Board is aware of the revised Charity Governance Code and use this guidance to support discussions about standards, behaviours and processes. Our plan for 2025 was to maintain focus on building resilience and sustainability for the future through succession planning, diversification of income streams and delivery of purposeful programs that continue to meet the ever-changing needs of people with diabetes.

Fundraising Regulator

We are a levy-paying member of the fundraising regulator and subscribe to the associated fundraising codes of practice. The charity suppresses individual supporter records against the Mailing Preference Service, Telephone Preference Service, and the Fundraising Preference Service, which helps to ensure that we do not approach individuals who have expressly requested that we do not contact them. During the year, we were notified of 9 FPS requests, which were suppressed from all contact, this is equal to the 9 received in 2024.

Corporate Partnerships

We do not endorse products, but we will support initiatives that increase awareness to DRWF and our activities, and where there is an appropriate message, product or service for people with diabetes. To this end, we have explored meaningful partnership and corporate sponsorship opportunities, where there is synergy in mission, vision and values. Any potential partnership is assessed for feasibility, compatibility with our own objectives, and risk to ensure there is no detrimental effect to our reputation, fundraising potential or the audiences that we exist to serve. Robust risk assessment supports our desire to only engage in suitable and best value partnerships. Detailed discussion and negotiation ensure that the aims of both parties are complementary and mutually beneficial and in line with any regulatory / industry standards. This maintains transparency and integrity in all partnerships.

A grant of £3,150 was secured from Pfizer Ltd. to support the development of a “Kidney and Diabetes” resource to raise awareness, empower self management and support early intervention. Pfizer Ltd. had no input into the content or process and development.

Investment Policy

Under the Memorandum of Articles of Association, the charity has the power to invest in any way the trustees see fit. The trustees are aware and mindful of the Charity Commission CC14 guidance on investments. The trustees, to minimise risk and having regard to the liquidity requirements of the charity, and to the reserves policy, have historically operated a policy of keeping available funds in a higher interest-bearing deposit account seeking to achieve a higher rate of deposit interest which matches or exceeds inflation as measured by the retail prices index.

The trustees have regularly reviewed opportunities to increase investment return from short-term, easy access, options bearing in mind the desire to ensure that we can react quickly to appropriate requests for additional research support as they arise.

The trustees are also conscious of on-going cash-flow requirements during a challenging time where historical fundraising methods are raising less income and where new methods of fundraising are being tested at higher cost.

All things considered, the trustees believe it appropriate to continue to explore investment opportunities as they present themselves, with a view to maximising return on its deposits.

Reserves Policy

To safeguard the need for sufficient funds to cover ongoing management, administration, and support costs, as well as respond to further grant requests that might arise, the Board aims to maintain unrestricted, free reserves at a level that equals 3-6 months of operating and charitable expenditures (£426,469 - £852,939).

On 31st December 2025, the charity held free reserves of £1,653,127 (unrestricted funds less tangible fixed assets). This equates to approximately 12 months of anticipated 2026 operating and charitable expenditures. Whilst this is significantly more than the policy level, the trustees are committed to strengthening existing income streams whilst diversifying fundraising activities to reduce reliance on single sources. It is accepted that this will take investment in activities where the accuracy of predicting response rates, in terms of volume or value of gift, will be more challenging in the first instance. Therefore, these additional reserves will enable us to explore avenues of diversification of income streams, and to develop the charity’s objective activities for future sustainability.

GDPR and Data Protection

We are committed to protecting the personal information and privacy of individuals that we engage with and comply with relevant legislation and codes of practice, whilst carrying out our essential work of raising awareness of diabetes, providing information and support, and raising funds. Our privacy policy, published at drwf.org. uk sets out how we capture, process, manage and retain personal information.

Going concern

Professional Fundraisers

Whilst we use the services of fundraising consultants, as and when needed, to advise on some of our activities, we did not work with a professional fundraiser during the year. Commercial participation agreements are in place where necessary.

Government Grants

The charity received no government grants for the period.

The trustees consider that there are no material uncertainties about the charity’s ability to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements having considered known commitments, forecasts and projections and possible pressures on income generation. After making these considerations, the trustees conclude that there is a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. The charitable company therefore continues to adopt the going concern basis in preparing the financial statements.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

CHARITY INFORMATION & GOVERNANCE

The trustees consider that the Charity has robust internal procedures, systems and processes and believe that risk assessment is embedded throughout the organisation.

How we raised our money -

Fundraising continued to be challenging in 2025, and this affected our actual income in the year which was £1,307,413 a shortfall of 1% on our budget expectation of £1,320,435 and 15% lower than income received in FYE 2024 at £1,534,027. The variance to last year is largely related to the reduced volume of direct mail campaigns that we distributed in the year, resulting in a lower value of donations alongside a reduction in legacy income in the year.

Financial review - Income:

Expenditure:

Total expenditure was £1,696,647 which was 1.6% above budget (£1,670,633), and 5% less than expenditure in 2024 (£1,792,042).

At year-end we had a deficit of £389,234. This was 11% more than we had anticipated when budgeting for the year where we had predicted a deficit of £350,198. Whilst expenditure in the year was in line with budget, the deficit was impacted quite significantly by the reduction in voluntary donations and fundraised income received in the year.

Direct charitable expenditure was 83p for every £1 spent (85p in 2024, 80p in 2023). We believe this demonstrates our commitment to spending income on delivering the services for which we exist to provide.

Total income was £1,307,413. This was 1% below budgeted income (£1,320,435) and 15% less than income received in 2024 (£1,534,027). Voluntary donations including gift aid receipts at £578,635 were 9% less than income received in 2024 (£637,145). Legacy, In Memory & Trust income was £449,047 which was 29% lower than received in 2024 (£628,727), as expected given the volume and value of legacies received and accounted for in the previous year. Grants received at £183,574 were 35% higher than 2024 at £135,578.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 TRUSTEES’ RESPONSIBILITIES

Trustees’ responsibilities in relation to the financial statements

The trustees, who are also directors of Diabetes Research and Wellness Foundation for the purposes of company law, are responsible for preparing the trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires trustees to prepare financial statements for each financial year that give a true and fair view of the state of the affairs of the charitable company and of the outgoing resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

In so far as the trustees are aware:

Auditors – Moore Kingston Smith LLP have indicated their willingness to continue in office and are deemed to be reappointed in accordance with section 487(2) of the Companies Act 2006.

Small Company Exemption – This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On Behalf of the Trustees

John Alahouzos Chairman

6/22/2026

Date:

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

INDEPENDENT AUDITOR’S REPORT

Independent Auditors’ Report

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF DIABETES RESEARCH AND WELLNESS FOUNDATION

Opinion

We have audited the financial statements of Diabetes Research and Wellness Foundation (‘the company’) for the year ended 31 December 2025 which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 INDEPENDENT AUDITOR’S REPORT FINANCIAL STATEMENTS

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 38, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

INDEPENDENT AUDITOR’S REPORT

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of noncompliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

22 June 2026

…………………………………........................……. Date: …….....……

Samir Chandoo (Senior Statutory Auditor)

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

6th Floor, 9 Appold Street, London, EC2A 2AP

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025FINANCIAL STATEMENTS

Diabetes Research and Wellness Foundation Statement of Financial Activities For the year ended 31 December 2025

Income
Note
Donations and Legacies
2
Charitable Activities
3
Other Charitable Trading Activities
4
Investments
Income from Charitable Activities
Other Income
5
Total Income
Expenditure On:
Raising Funds
6
Charitable Activities
7
Net Income
Net Movement in Funds
Total Funds brought forward
Total funds carried forward at 31 December 2025		 Unrestricted
Funds
£
952,005
72,298
28,290
40,739
1,093,332
27,128
1,120,460
286,182
1,222,088
1,508,270
(387,810)
(387,810)
2,048,458
1,660,648		 Restricted
Funds
£
3,379
183,574
-
-
186,953
-
186,953
-
188,377
188,377
(1,424)
(1,424)
7,953
6,529		 2025
TOTAL
£
955,384
255,872
28,290
40,739
1,280,285
27,128
1,307,413
286,182
1,410,465
1,696,647
(389,234)
(389,234)
2,056,411
1,667,177		 Unrestricted
Funds
£
1,157,904
80,015
56,049
56,351
1,350,319
20,177
1,370,496
265,718
1,300,062
1,565,780
(195,284)
(195,284)
2,243,742
2,048,458		 Restricted
Funds
£
27,953
135,578
-
-
163,531
-
163,531
-
226,262
226,262
(62,731)
(62,731)
70,684
7,953		 2024
TOTAL
£
1,185,857
215,593
56,049
56,351
1,513,850
20,177
1,534,027
265,718
1,526,324
1,792,042
(258,015)
(258,015)
2,314,426
2,056,411

There were no recognised gains or losses other than the deficit reported for the financial year. All activities in the year relate to continuing operations.

The accompanying notes form an integral part of these financial statements.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Balance Sheet As at 31 December 2025

----- Start of picture text -----
Note 2025 2025 2024 2024
£ £ £ £
Fixed Assets
Tangible Assets 15
7,521 8,786
Current Assets
Debtors 16 610,030 655,293
Investments 434,663 433,101
Cash at bank and in hand 1,129,758 1,418,968
2,174,451 2,507,362
Creditors : Amounts falling due
within one year 17 (514,795) (459,737)
Net Current Assets 1,659,656 2,047,625
Total Net Assets 1,667,177 2,056,411
Reserves
Restricted Fund 19 6,529 7,953
General Reserve 19 1,660,648 2,048,458
1,667,177 2,056,411
----- End of picture text -----

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and with the FRS 102 Charity SORP.

6/22/2026

The financial statements were approved, and authorised for distribution, by the Trustees on ……………………….. and signed on their behalf by:

………………………………………................................. Trustee John Alahouzos

The accompanying notes form an integral part of these financial statements

Company number: 03496304

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Statement of Cash Flows For the year ended 31 December 2025

Note
Cash used in Operating Activities
23
Cash Flows from Investing Activities
Interest on Bank Deposit
Investments
Fixed Assets
Cash Flows from Financing Activities
Change in cash and cash equivalents in the year
Cash and cash equivalents brought forward 1st January
Cash and cash equivalents at 31st December 2025		 40,739
(1,562)
(2,268)		 2025
£
(326,119)
36,909
-
(289,210)
1,418,968
1,129,758		 56,351
(8,843)
0		 2024
£
(91,871)
47,508
-
(44,363)
1,463,331
1,418,968

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements For the year ended 31 December 2025

1 Accounting Policies

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charitable Company is a public benefit company for the purposes of FRS 102 and therefore the Charity also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the charity to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the charity's forecasts and projections and have taken account of pressures on donations income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest pound. The financial statements have been prepared on the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Critical accounting estimates and areas of judgement

In the view of the trustees in applying the accounting policies adopted, no judgements were required that have a significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions made carry a significant risk of material adjustment in the next financial year.

The principal accounting policies of the charity are set out below:

Income

Income is included on an accruals basis except that donations under gift aid together with the associated income tax recoveries are credited as income when the donations are received. Membership Subscriptions are apportioned across the membership subscription period. Income from gift aid repayment claims is only included for claims which have been submitted for tax periods ending on or before the year end and when the receipt of this income is certain.

Legacies

Legacies are recognised following probate and once there is sufficient evidence that receipt is probable and the amount of the legacy receivable can be measured reliably. Where entitlement to a legacy exists but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met.

Public Donations and Gifts-in-Kind

Incoming resources in the form of Gifts-in-Kind are included in the Statement of Financial Activities only when assets donated to the charity are distributed. Gifts-in-Kind are donations of commodities directly usable in charitable programmes, such as food, blankets, books, agricultural and medical supplies. The Charity has an internationally recognised and accepted monitoring programme in place to ensure that commodities are appropriately valued at wholesale or less, culturally appropriate for the designated programme, and can be both properly shipped and distributed gratis to the designated beneficiaries.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

1 Accounting Policies (continued)

Expenditure

Expenditure, which is charged on an accruals basis, is allocated between:

Charitable expenditure comprises all the expenditure incurred by the charity in meeting its charitable objectives and is further analysed between:

Cost Apportionment

Where items of expenditure involve more than one cost category these costs have been apportioned on a reasonable basis as determined by the trustees. One particular area where the cost is material to the charity is in the production and distribution of direct mailings.

One of the purposes of the mail shot is to develop a database of names of people with a particular interest in the activities of the charity and its charitable objects. It is held that individuals who make a £10 or greater donation, in response to the mailing, have a degree of interest in diabetes. They are interested because they suffer from diabetes, know somebody who does or could themselves be at risk of developing the condition. These are precisely the people whom the charity is trying to help and consequently they receive the benefits of the educational material provided by the charity. These high interest individuals constitute 25% of the total responses; so the charity allocates 25% of the cost of the mailing to costs in furtherance of the charity's objects.

Furthermore the remaining expenditure has been allocated on the basis of whether the educational content of the individual mailing is significantly high enough so as to be material. When this holds true the remaining cost of the mailing is allocated on a pro-rata basis comparing the educational content (costs in furtherance of the charity's objects) to the fund raising content (costs of generating funds). The educational content is determined by the amount of text and space on each mailing that is dedicated to material of an educational nature.

Telemarketing expenditure is allocated in a consistent manner with mailings, as described above, hence the charity allocates 25% of the cost of the telemarketing calls to costs in furtherance of the charity's objectives, with the remaining expenditure allocated on the basis of whether the time spent during the telephone call is in accordance with the charity's objects or otherwise.

Fund raising expenditure i.e. Text that may induce a donation from the recipient, is allocated upon the basis of the volume of the text and space that is not related to text of an educational nature.

Support costs comprise all other overhead costs for the running of the charity as an organisation.

Fund Accounting

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. The aim and use of each fund is set out in the notes to the financial statements.

Unrestricted funds are donations and other incoming resources received or generated for expenditure on the general objectives of the charity.

Restricted funds are donations received from a donor who has specified a particular area of the charity's work to which the donation should be allocated.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

1 Accounting Policies (continued)

Grants Payable

Grants are recognised when they become due for payment. Included within the Statement of Financial Activities is the cost of grant instalments that are payable to charitable organisations / individuals in accordance with the charity's governing instruments, together with any grants payable for the year, but not paid by the year end date. The value of grants awarded which are subject to the completion of a future year's performance is disclosed as a Financial Commitment in Note 21.

Tangible Fixed Assets and Depreciation

Depreciation is calculated to write down the cost less estimated residual value of all tangible fixed assets held for charity use by equal annual instalments over their expected useful economic lives. The rates generally applicable are:

Office equipment, fixtures and fittings

5-7 years straight line

All tangible fixed assets costing more than £250 are capitalised at their cost to the charity.

Foreign Currencies

Transactions in foreign currencies are translated at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. All exchange differences are dealt with through the statement of

Leasing Commitments

Rentals payable under operating leases are charged against income on a straight line basis over the

Other Financial Instruments

i. Cash and cash equivalents

Cash and cash equivalents include cash at banks and in hand and short term deposits with a maturity date of less than 95 days.

ii. Investments

Current asset investments include deposits with a maturity date of 95 days or more.

iii. Debtors and Creditors

Debtors and creditors receivable or payable within one year of the reporting date are carried at their at transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

2
Donations and Legacies
2025
£
Donations
500,170
Lottery Programme
6,167
Legacies Received
449,047
955,384
Included in the above are restricted donations and legacies of £3,379 (2025: £27,953)
3
Charitable Activities
2025
£
Grants Received
183,574
Gift Aid Receipts
72,298
255,872
Included in the above are restricted grants of £183,574 (2025: £135,578)
4
Other Charitable Trading Activities
2025
£
Membership Subscriptions
4,777
Event Fees and Sponsorship
23,513
28,290
5
Other income
2025
£
Miscellaneous Income
27,128
27,128
6
Fund Raising Costs
2025
£
Caging
80,303
Carriers
350
Computer Charges
2,457
Lettershop and Data
1,045
Postage and Shipping
5,309
Printing
1,690
Publicity
419
Marketing Costs
8,975
Community Fundraising
49,163
Mail Pack Premiums
3,365
Lottery Costs
2,639
Staff Costs (see Note 11)
130,467
Sweepstake Winners
-
286,182
7
Charitable Activities
2025
2025
2025
Direct
Grants
Expenditure
Awards
(Note 9)
(Note 8)
(Note 10)
£
£
£
Research into the Relief of Diabetes
-
279,875
537,458
Raising Public Awareness of Diabetes
593,132
-
-
593,132
279,875
537,458
2024
2024
2024
Direct
Grants
Expenditure
Awards
(Note 9)
(Note 8)
(Note 10)
£
£
£
Research into the Relief of Diabetes
-
398,189
415,949
Raising Public Awareness of Diabetes
712,186
-
-
712,186
398,189
415,949
Support Costs
Support Costs		 2024
£
549,888
7,242
628,727
1,185,857
2024
£
135,578
80,015
215,593
2024
£
6,106
49,943
56,049
2024
£
20,177
20,177
2024
£
79,115
79
2,736
1,745
9,869
403
681
-
21,662
15,972
3,237
130,444
225
-
265,718
2025
Total
£
817,333
593,132
1,410,465
2024
Total
£
814,138
712,186
1,526,324

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

8
Grant Awards
University of Oxford
Cardiff University - Non Clinical Fellowship 2021
University of East Anglia - Clinical Fellowship 2021
University College London/Liverpool University - Non Clinical Fellowship 2022
2024 Pump Priming Awards
BHR Ltd - Islet Transplant
Autek CIC - Autism and Diabetes
University of Cambridge - Clinical Fellowship 2025
Less: Unclaimed grants written back		 2025
£
181,648
0
6,584
0
0
12,500
2,800
80,002
283,534
(3,659)
279,875		 2024
£
172,614
5,415
79,003
56,719
119,982
900
0
0
434,633
(36,444)
398,189

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

9
Direct Charitable Expenditure
Staff Costs (see Note 11)
Postage
Printing
Mail Pack Premiums
Educational Events
Carriers
Grant Costs
Lettershop and Data
10
Support Costs
Other Staff Costs
Professional Costs
Management Charge
Office Expenses
Establishment Expenses
Bank Charges and Interest Paid
Foreign Exchange Loss
Depreciation
Irrecoverable VAT
Amounts paid to Auditors
Company Secretarial Fees
Board Meeting Expenses & Trustee Expenses
Other Overhead Costs		 2025
£
375,116
65,222
36,249
37,622
61,381
3,908
1,208
12,426
593,132
2025
£
3,131
41,510
147,395
89,017
52,091
4,036
4,792
3,533
156,157
20,624
704
-
14,468
537,458		 2024
£
327,458
88,321
23,490
151,978
108,780
750
404
11,005
712,186
2024
£
1,565
22,405
152,450
70,981
46,156
5,554
2,967
3,389
66,398
21,916
513
10,512
11,143
415,949

Support Costs are allocated to the Charitable expenditure of the charity in proportion to the direct cost of the activity

11
Wages and Salaries
Wages and Salaries
Social Security Costs
Pension Costs		 2025
£
447,787
42,800
14,996
505,583		 2024
£
410,414
34,206
13,282
457,902

The key management personnel of the charity are the Trustees and the CEO. The total amount paid for key management personnel was £77,902 (2024: £74,652).

personnel was £77,902 (2024: £74,652).
2025 2024
No. No.
The number of higher paid employees was in the band:
£60,000 - £70,000 1 1

Pension contributions payable for the above individual was £2,974 (2024: £2,887).

The number of employees at the end of the year was 14 (2024: 13).

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

12 Payments to Trustees

No trustee or person with a family or business connection with a trustee, received remuneration in the year, directly or indirectly, from the charity.

Reimbursement to Trustees for Travel and Meeting Costs were £nil (2024: £6,551 for 3 trustees).

13
Surplus of Income over Expenditure
The surplus of income over expenditure is stated after charging:
Auditors' Remuneration:
- Audit Fee relating to the Financial Year
- In respect of non audit services
Operating Lease rentals
- Plant & Machinery
- Other Assets
Foreign Exchange Loss
Depreciation		 2025
£
20,200
1,425
3,779
22,871
4,792
3,533		 2024
£
23,995
1,350
3,185
22,871
2,967
3,389

14 Taxation

The company, being a registered charity, is not liable for corporation tax in respect of its charitable operations for the year.

15 Tangible Fixed Assets for Charity Use

ange xe sses or ary se
Cost
At 1 January 2025
Additions in Year
Disposals in Year
At 31 December 2025
Depreciation
At 1 January 2025
Provided in the year
Eliminated on Disposal
At 31 December 2025
Net Book Value
At 31 December 2025
At 31 December 2024
16
Debtors
Trade Debtors
Other Debtors
Prepayments and Accrued Income		 2025
£
4,434
356
605,240
610,030		 Office
equipment,
fixtures and
fittings
£
18,956
2,268
(645)
20,579
10,170
3,533
(645)
13,058
7,521
8,786
2024
£
7,740
8,792
638,761
655,293

All Debtors except prepayments are financial instruments and are measured at settlement value

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583 FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

17
Creditors : Amounts falling due within one year
Trade Creditors
Grants Payable (see below)
Accruals and Deferred Income
Tax and Social Security
Other Creditors
All Creditors except deferred income are financial instruments and are measured at settlement value
Reconciliation of Grants Payable:
Commitments at 1 January 2025
Grants Committed to in the Year (see Note 8)
Grants Paid during Year		 2025
£
28,211
334,816
132,793
18,975
-
514,795
363,542
279,875
(308,601)
334,816		 2024
£
42,118
363,542
40,515
13,562
-
459,737
248,706
398,189
(283,353)
363,542

In addition to the amounts committed and accrued noted above, the trustees have also authorised the continuation of certain grants which are subject to the recipient fulfilling certain conditions. The details of these further commitments can be found in Note 21.

18
Deferred Income
Deferred Income B/FWD 1st January 2025
Released to Income in Year
Income Deferred In Year
Deferred Income C/FWD 31st December 2025		 2025
£
8,238
(8,238)
1,851
1,851		 2024
£
5,576
(5,576)
8,238
8,238

Deferred Income comprises:

19
Reserves
Restricted Fund relating to Diabetes Research (grant)
Restricted Fund relating to The Big Give Christmas Challenge
Restricted Fund relating to Diabetes Resources (Kidney Health)
General Reserve
Restricted Fund relating to Diabetes Research (grant)
Restricted Fund relating to The Big Give Christmas Challenge
Restricted Fund relating to Diabetes Research (legacy)
General Reserve		 £
-
7,953
-
2,048,458
2,056,411
£
48,710
21,974
-
2,243,742
2,314,426
Balance at
1 January
2025
Balance at
1 January
2024		 £
180,424
3,379
3,150
1,120,460
1,307,413
£
135,578
7,953
20,000
1,370,496
1,534,027
Income in
Year
Income in
Year		 £
(180,424)
(7,953)
-
(1,508,270)
(1,696,647)
£
(184,288)
(21,974)
(20,000)
(1,565,780)
(1,792,042)
Expenditure
in Year
Expenditure
in Year		 £
-
(4,574)
3,150
(387,810)
(389,234)
£
(48,710)
(14,021)
-
(195,284)
(258,015)
Net
Movement in
Year
Net
Movement in
Year		 £
-
3,379
3,150
1,660,648
Balance at
31 December
2025
1,667,177
£
-
7,953
-
2,048,458
Balance at
31 December
2024
2,056,411

During 2025 the charity participated in the Big Give Christmas Challenge 2025 to raise funds for a research grant. The funds received in the year was £3,379 (2024 £7,953).

Net Assets by Fund
Tangible Assets
Current Assets
Current Liabilities		 Unrestricted
£
7,521
2,167,922
(514,795)
1,660,648		 Restricted
£
-
6,529
-
6,529		 Total
£
7,521
2,174,451
(514,795)
1,667,177

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Diabetes Research and Wellness Foundation Notes to the Financial Statements (continued) For the year ended 31 December 2025

20 Transactions With Connected Charities

Nature of Type of 2025 2025 2024 2024
Connected Charity Relationship Transaction £ £ £ £ Nature of Transactions
Total Balance at Total Balance at
transactions the year end transactions the year end
in the year in the year
Diabetes Research and Wellness 1 Payment 147,395 - 152,450 - Management charges in relation
Foundation Inc. to the sharing of articles and staff.
Imsamlingsstiftelsen Diabetes
Wellness Network Sverige		 2 Payment 2,856 - - - Reimbursement of marathon
places.
Imsamlingsstiftelsen Diabetes
Wellness Network Sverige		 2 Receipt 178,424 - - - Grant - Islet isolation facility.
Imsamlingsstiftelsen Diabetes
Wellness Network Sverige		 2 Receipt 18,000 - 18,000 - Grant support administration.
Imsamlingsstiftelsen Diabetes
Wellness Network Sverige		 2 Receipt 24,164 - 20,426 - Reimbursement of expenses
incurred on behalf of IDWNS.

Further details regarding the relationship can be found in the Trustees Report.

21 Financial Commitments

The charity has financial commitments of £390,211 (2024: £277,195) for grants authorised but not accrued as expenditure for the year ended 31 December 2025, as they are subject to the recipient fulfilling certain conditions. The amounts payable are as follow:

Payable in 2025
Payable in 2026
Payable in 2027
Payable in 2028
Payable in 2029		 2025
£
-
149,954
109,152
82,803
48,302
390,211		 2024
£
153,007
97,840
26,348
-
-
277,195

22 Operating Leases

At 31st December 2025, the charity has commitments under operating leases as follows:

Land and Buildings
Other Assets
Total		 2025
2025
£
£
Within one
Two to Five
Year
Years
13,417
50,935
2,586
2,073
16,003
53,008		 2024
£
Within one
Year
24,950
2,586
27,536		 2024
£
Two to Five
Years
1,982
4,658
6,640

The Charity's office lease was renewed on 3rd March 2026 from 31st January 2026 with a term of three years.

23
Reconciliation of Net Movement in Funds to Net Cash Flow from Operating Activities
Net Movement in Funds - Surplus/(Deficit)
Add back Depreciation Charge
Deduct Interest Income shown in Investing Activities
Decrease (Increase) in Debtors
Increase (Decrease) in Creditors
Net Cash used in Operating Activities		 2025
£
(389,234)
3,533
(40,739)
45,263
55,058
(326,119)		 2024
£
(258,015)
3,389
(56,351)
153,086
66,020
(91,871)

24 Members' Liability

The Foundation is a company limited by guarantee. In the event of winding up, the 5 members' liability is limited to £1.

Docusign Envelope ID: D2A06FDC-5F98-8C3F-825D-B8AB0C90D583

Our aims are threefold

Diabetes, whatever the type, is a complex long-term condition but from diagnosis, with the right treatment and support, it can be managed effectively.

Our programmes are designed to ... inform, inspire, empower and support.

Don’t let diabetes prevent you from living a full and healthy life. Don’t let diabetes control you!

We fund some of the best and brightest diabetes researchers in the UK and around the world. We award Clinical and NonClinical Fellowships; fund Pump Priming (proof of concept) projects; and contribute to long-standing programmes through institutional and contract funding. We are members of the Association of Medical Research Charities (AMRC) and operate a robust peer review process on all applications for funding, so that you can be assured we are spending donations wisely and funding the work most likely to deliver positive results.

Together, we are investing in a brighter future for people with diabetes and ensuring that those living with diabetes are ‘staying well until a cure is found…’

THANK YOU

To find out more about out work, to join our Diabetes Wellness Network, or to donate

www.drwf.org.uk

Diabetes Research & Wellness Foundation (DRWF) Building 1000 Langstone Park Havant ~~PO~~ 9 1SA Hampshire

Registered Charity in England & Wales, Registration no: 1070607 Company Limited by Guarantee, Company no: 03496304

Diabetes Research & Wellness Foundation